Literature DB >> 6175937

Quantitated determination of proteins in perilymph in patients with acoustic neuromas.

J Thomsen, O Saxtrup, M Tos.   

Abstract

Perilymph, cerebrospinal fluid (CSF) and plasma from 19 patients with acoustic neuromas were examined for albumin, alpha 2-macroglobulin and IgG. Patients with otosclerosis were used as controls. A highly significant increase of the tested proteins was found in perilymph from patients with acoustic neuromas. Determination of the tau-transferrin, which is a specific CNS protein, could neither be demonstrated in plasma nor in perilymph. This is in favour of the assumption that perilymph is plasma-derived and not concentrated CSF. Various causes for the high protein concentrations are discussed, and it is suggested that the increase is caused by a blockage of the neuroaxonal transport mechanisms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175937     DOI: 10.1159/000275574

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  11 in total

1.  Increased signal intensity of the cochlea on pre- and post-contrast enhanced 3D-FLAIR in patients with vestibular schwannoma.

Authors:  Masahiro Yamazaki; Shinji Naganawa; Hisashi Kawai; Takashi Nihashi; Hiroshi Fukatsu; Tsutomu Nakashima
Journal:  Neuroradiology       Date:  2009-12       Impact factor: 2.804

2.  Signal intensity change of the labyrinth in patients with surgically confirmed or radiologically diagnosed vestibular schwannoma on isotropic 3D fluid-attenuated inversion recovery MR imaging at 3 T.

Authors:  In Ho Lee; Hyung-Jin Kim; Won Ho Chung; Eunhee Kim; Jung Won Moon; Sung Tae Kim; Keon Ha Kim; Pyoung Jeon; Hong Sik Byun
Journal:  Eur Radiol       Date:  2009-11-07       Impact factor: 5.315

3.  Endolympathic hydrops in patients with vestibular schwannoma: visualization by non-contrast-enhanced 3D FLAIR.

Authors:  Shinji Naganawa; Hisashi Kawai; Michihiko Sone; Tsutomu Nakashima; Mitsuru Ikeda
Journal:  Neuroradiology       Date:  2011-01-11       Impact factor: 2.804

4.  Radiosurgery of vestibular schwannoma: prognostic factors for hearing outcome using 3D-constructive interference in steady state (3D-CISS).

Authors:  Franca Wagner; Matteo Gandalini; Arsany Hakim; Ekin Ermis; Dominic Leiser; Martin Zbinden; Lukas Anschuetz; Andreas Raabe; Marco Caversaccio; Roland Wiest; Evelyn Herrmann
Journal:  Strahlenther Onkol       Date:  2018-09-10       Impact factor: 3.621

5.  Decreased vestibular signal intensity on 3D-FIESTA in vestibular schwannomas differentiating from meningiomas.

Authors:  Kazuhiro Ishikawa; Jun Haneda; Kouichirou Okamoto
Journal:  Neuroradiology       Date:  2012-10-16       Impact factor: 2.804

6.  Clinical significance of an increased cochlear 3D fluid-attenuated inversion recovery signal intensity on an MR imaging examination in patients with acoustic neuroma.

Authors:  D Y Kim; J H Lee; M J Goh; Y S Sung; Y J Choi; R G Yoon; S H Cho; J H Ahn; H J Park; J H Baek
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

7.  Increased cochlear fluid-attenuated inversion recovery signal in patients with vestibular schwannoma.

Authors:  R A Bhadelia; K L Tedesco; S Hwang; S H Erbay; P H Lee; W Shao; C Heilman
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-31       Impact factor: 3.825

8.  Audiovestibular Function Deficits in Vestibular Schwannoma.

Authors:  Constantin von Kirschbaum; Robert Gürkov
Journal:  Biomed Res Int       Date:  2016-09-22       Impact factor: 3.411

9.  Differentiation of vestibular schwannomas from meningiomas of the internal auditory canal using perilymphatic signal evaluation on T2-weighted gradient-echo fast imaging employing steady state acquisition at 3T.

Authors:  A Venkatasamy; D Le Foll; A Karol; B Lhermitte; A Charpiot; C Debry; F Proust; N Meyer; F Veillon
Journal:  Eur Radiol Exp       Date:  2017-06-29

10.  Mechanisms of hearing loss in neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Raul A Vasquez; John A Butman; Tianxia Wu; Keaton Morgan; Carmen C Brewer; Kelly King; Chris Zalewski; H Jeffrey Kim; Russell R Lonser
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.